Akari Therapeutics, Plc
AKTX
$0.92
-$0.005-0.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 39.07% | -8.17% | -97.75% | -116.37% | -103.56% |
| Total Depreciation and Amortization | -93.33% | -93.75% | 250.00% | 250.00% | 275.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -65.72% | 631.02% | 112.33% | 101.57% | 105.83% |
| Change in Net Operating Assets | -18.30% | 325.33% | 855.08% | 566.02% | 35.84% |
| Cash from Operations | 42.90% | 31.66% | 23.61% | 7.06% | 9.50% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -97.40% | -- | -- | 102,700.00% | -- |
| Total Debt Repaid | -273.08% | -901.86% | -- | -- | -- |
| Issuance of Common Stock | -26.73% | 132.41% | 70.25% | 23.86% | -24.86% |
| Repurchase of Common Stock | -13,500.00% | -13,500.00% | -13,500.00% | -13,500.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -43.53% | 118.09% | 56.52% | 23.96% | -22.10% |
| Foreign Exchange rate Adjustments | 450.00% | -50.00% | -157.14% | -96.68% | -103.32% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 53.20% | 112.97% | 87.39% | 58.37% | -209.69% |